Spence is currently working as a consultant to the consumer packaged goods industry. Spence has served as a director since April 2009. Eiref's 30 years of financial management and operations experience in the consumer packaged goods and cosmetics industries, and specialized knowledge of financial statements and the accounting and treasury functions, make him well-qualified to serve on our Board. He graduated from Oxford University, and is an English Chartered Accountant. Eiref serves on the board of Unigene Laboratories, Inc., as well as certain private and non-profit organizations. Earlier in his career, he worked for Unilever and Arthur Andersen in Europe. From 1988 to 1995, he served as Chief Financial Officer of Chanel Inc., the fashion, fragrance and cosmetics company. Eiref served as Chief Financial Officer of Church & Dwight, Co., a manufacturer and marketer of a wide range of household and personal care products under the Arm & Hammer, Trojan, First Response, and other well-known trademarks. For a total of 20 years, from 1979 to 1988, and again from 1995 to 2006, Mr. Zvi Eiref has served as a director since August 2007. Jackel’s long-standing service to Physicians Formula in a variety of leadership roles, she has an unparalleled understanding of our business which makes her uniquely qualified to serve as Chairwoman of our Board. Ms. Jackel was awarded the Women’s Wear Daily prize for the “most innovative marketer of the year” in mass market cosmetics in 2003. and France for cosmeceutical brands owned by the Pierre Fabre group, such as Avene, Elancyl and Aderma. Prior to her involvement in the Physicians Formula brand, Ms. Jackel served in a variety of marketing management roles in the U.S. Jackel served in a variety of management roles, including Vice President of Marketing for Physicians Formula from May 1998 to March 2003 and Director of Marketing for Physicians Formula from July 1997 to April 1998. subsidiary of Pierre Fabre Dermo-Cosmetique, S.A., a large French pharmaceutical and cosmeceutical company. (“Pierre Fabre”), formerly a wholly-owned U.S. In 1994, Ms. Jackel joined the then-current owner of the Physicians Formula brand, Pierre Fabre, Inc. Ms. Jackel oversees all aspects of our marketing, research and development and quality control functions. Jackel served as Senior Vice President-Marketing of the Company. Ingrid Jackel has served as chairwoman of our Board since January 2008, as a director since September 2006, and as our Chief Executive Officer since August 2006. If you received a Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials contained on the Notice. The Notice also instructs you on how you may submit your proxy over the Internet.
#Where go buy ez record address book how to
Instead, the Notice instructs you on how to access and review all of the important information contained in the proxy statement and annual report. If you received a Notice by mail, you will not receive a printed copy of the proxy materials in the mail. On or about April 21, 2010, a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this proxy statement and our 2009 Annual Report on Form 10-K was mailed to beneficial owners of our common stock (i.e., holders who hold their shares in “street name”). Proposed maximum aggregate value of transaction:įee paid previously with preliminary materials.Īs permitted by rules adopted by the Securities and Exchange Commission, in order to reduce costs and the environmental impact, we are making this proxy statement and our 2009 Annual Report on Form 10-K available to our stockholders electronically via the Internet. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Title of each class of securities to which transaction applies:Īggregate number of securities to which transaction applies: Payment of Filing Fee (Check the appropriate box):įee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (Name of Person(s) Filing Proxy Statement, if other than the Registrant) (Name of Registrant as Specified In Its Charter) Soliciting Material Pursuant to §240.14a-12 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
0 kommentar(er)
